Indivior PLC (NASDAQ:INDV – Get Free Report) shares were down 4.2% during trading on Wednesday . The stock traded as low as $9.33 and last traded at $9.41. Approximately 179,048 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 373,577 shares. The stock had previously closed at $9.82.
Wall Street Analyst Weigh In
INDV has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $22.00 price target on shares of Indivior in a research note on Friday, September 13th. Craig Hallum decreased their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.
Get Our Latest Stock Analysis on Indivior
Indivior Stock Performance
Indivior (NASDAQ:INDV – Get Free Report) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. The firm had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. On average, research analysts predict that Indivior PLC will post 1.7 earnings per share for the current fiscal year.
Institutional Trading of Indivior
Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its stake in shares of Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after acquiring an additional 6,121 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Indivior during the 2nd quarter worth about $188,000. VELA Investment Management LLC purchased a new stake in shares of Indivior during the second quarter worth about $235,000. XTX Topco Ltd acquired a new position in shares of Indivior in the second quarter valued at approximately $249,000. Finally, Chilton Investment Co. Inc. acquired a new position in shares of Indivior in the fourth quarter valued at approximately $263,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Momentum Trades for October With Ample Upside Ahead
- Do ETFs Pay Dividends? What You Need to Know
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Manufacturing Stocks Investing
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.